Vivimed Labs Ltd
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.[1]
- Market Cap ₹ 41.0 Cr.
- Current Price ₹ 4.95
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 12.0
- Dividend Yield 0.00 %
- ROCE -44.5 %
- ROE -111 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.41 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -7.52% over past five years.
- Promoter holding is low: 20.9%
- Company has a low return on equity of -31.6% over last 3 years.
- Contingent liabilities of Rs.123 Cr.
- Promoters have pledged 37.1% of their holding.
- Promoter holding has decreased over last 3 years: -7.64%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
383 | 423 | 432 | 430 | 319 | 570 | 261 | 252 | 277 | 210 | 218 | 177 | 140 | |
298 | 328 | 328 | 323 | 233 | 319 | 183 | 184 | 237 | 182 | 227 | 365 | 309 | |
Operating Profit | 85 | 95 | 104 | 107 | 86 | 250 | 78 | 67 | 40 | 28 | -9 | -188 | -169 |
OPM % | 22% | 22% | 24% | 25% | 27% | 44% | 30% | 27% | 14% | 13% | -4% | -106% | -120% |
0 | 3 | 2 | 1 | 1 | 9 | 2 | 9 | -0 | 6 | 1 | 0 | 2 | |
Interest | 24 | 30 | 49 | 64 | 57 | 59 | 53 | 53 | 43 | 42 | 40 | 36 | 44 |
Depreciation | 11 | 17 | 18 | 21 | 19 | 27 | 18 | 18 | 17 | 16 | 17 | 107 | 109 |
Profit before tax | 51 | 51 | 39 | 24 | 11 | 173 | 9 | 5 | -21 | -24 | -65 | -330 | -319 |
Tax % | 21% | 28% | 31% | 22% | 28% | 27% | -12% | -20% | -8% | -1% | 4% | -1% | |
40 | 37 | 27 | 19 | 8 | 126 | 10 | 6 | -19 | -23 | -68 | -328 | -316 | |
EPS in Rs | 5.80 | 4.58 | 3.29 | 2.34 | 1.00 | 15.59 | 1.20 | 0.75 | -2.31 | -2.81 | -8.17 | -39.56 | -38.10 |
Dividend Payout % | 10% | 13% | 2% | 0% | 0% | 3% | 33% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -8% |
5 Years: | -8% |
3 Years: | -14% |
TTM: | -26% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -286% |
Stock Price CAGR | |
---|---|
10 Years: | -24% |
5 Years: | -20% |
3 Years: | -38% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | -5% |
5 Years: | -17% |
3 Years: | -32% |
Last Year: | -111% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 14 | 16 | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
Reserves | 262 | 328 | 356 | 358 | 353 | 545 | 551 | 556 | 537 | 508 | 441 | 117 | 83 |
419 | 444 | 636 | 698 | 599 | 571 | 446 | 348 | 304 | 323 | 357 | 377 | 348 | |
83 | 167 | 195 | 231 | 397 | 229 | 243 | 234 | 210 | 247 | 258 | 363 | 298 | |
Total Liabilities | 777 | 955 | 1,203 | 1,303 | 1,365 | 1,361 | 1,255 | 1,155 | 1,067 | 1,095 | 1,072 | 873 | 746 |
294 | 405 | 397 | 377 | 387 | 433 | 405 | 381 | 356 | 416 | 429 | 343 | 334 | |
CWIP | 8 | 9 | 16 | 63 | 41 | 59 | 43 | 64 | 70 | 58 | 40 | 21 | 21 |
Investments | 87 | 96 | 228 | 230 | 230 | 88 | 152 | 88 | 88 | 161 | 161 | 161 | 161 |
388 | 445 | 563 | 633 | 708 | 781 | 656 | 622 | 554 | 459 | 442 | 349 | 230 | |
Total Assets | 777 | 955 | 1,203 | 1,303 | 1,365 | 1,361 | 1,255 | 1,155 | 1,067 | 1,095 | 1,072 | 873 | 746 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
106 | 44 | -45 | 41 | -54 | 28 | 207 | 82 | 75 | 180 | 25 | 33 | |
-277 | -108 | -149 | -50 | -11 | 30 | -38 | 56 | 3 | -138 | -11 | -2 | |
182 | 58 | 193 | 9 | 59 | -50 | -175 | -123 | -91 | -46 | -13 | -35 | |
Net Cash Flow | 11 | -6 | -0 | 1 | -7 | 8 | -6 | 15 | -13 | -5 | 1 | -3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94 | 138 | 155 | 194 | 264 | 144 | 234 | 148 | 118 | 133 | 106 | 109 |
Inventory Days | 118 | 214 | 265 | 410 | 744 | 579 | 1,236 | 1,284 | 640 | 954 | 608 | 216 |
Days Payable | 44 | 71 | 61 | 84 | 68 | 92 | 99 | 160 | 75 | 124 | 95 | 96 |
Cash Conversion Cycle | 168 | 280 | 359 | 520 | 940 | 632 | 1,371 | 1,271 | 683 | 963 | 619 | 230 |
Working Capital Days | 259 | 284 | 355 | 379 | 625 | 364 | 706 | 685 | 566 | 676 | 611 | 504 |
ROCE % | 14% | 11% | 10% | 8% | 7% | 22% | 6% | 6% | 3% | 2% | -3% | -44% |
Documents
Announcements
- Closure of Trading Window 26 Sep
-
Board Meeting Outcome for Outcome Of Board Meeting
6 Sep - Deferment of audited financial results and AGM extension.
-
Board Meeting Intimation for Notice Of Board Meeting / Closure Of Trading Window
23 Aug - Notice of Board Meeting and trading window closure.
-
Results-Delay in Financial Results
22 Aug - Resignation of auditors due to NFRA order.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 16 Aug
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Aug 2019TranscriptNotesPPT
-
Mar 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Aug 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016Transcript PPT
-
May 2016Transcript PPT
-
Aug 2015TranscriptNotesPPT
API Division (~69% of revenues)[1]
This is the flagship division of the company which is primarily managed by its subsidiary UQUIFA s.a. based in Spain. The division further has 2 sub-divisions :-[2]